Home   |  İrtibat   |  Yerler
Safe Infusion Therapy (TR)
 
Home >

Finansal Sonuçlar

Ekonomik sonuçlar

İnsanların ve özellikle de gelişmekte olan çocukların DEHP'ye maruz kalması yukarıda (bkz. Sağlığa İlişkin Sonuçlar, Şekil 14) gösterildiği üzere önemli sağlık sorunlarına yol açabilir.
Bu bozukluklar önemli ekonomik sonuçlara yol açarken daha ciddi hastalıklar da yüksek ekonomik sıkıntılara yol açar.

Şekil 16: DEHP'ye maruz kalmanın neden olduğu komplikasyonların bir sonucu olarak olası ek maliyetlere ilişkin tahmin. Her komplikasyonun maliyet hesaplamasına katılmasını kolaylaştırmak için vaka ağırlık düzeyleri (Dean & Barber Scale 1) kullanıldı.

Şekil 16'nın referansları:

Bu dış linke bağlanarak bu web sitesinden ayrılmak üzeresiniz. B. Braun açmak üzere olduğunuz web sitesinin sahibi değildir ve içeriğini de kontrol etmemektedir.

1The Straits Times, Thu, Oct 29, 2009

2The costs of myocardial infarction-a longitudinal analysis using data from a large German health insurance company Reinhold T, Lindig C, N. Willich S, Brüggenjürgen B. Journal of Public Health 2011 19:6 (579-586)

2Cost of myocardial infarction to the Australian community: A prospective, multicentre survey Ioannides-Demos L.L., Makarounas-Kirchmann K, Stoelwinder J, McNeil JJ, Ashton E. Clinical Drug Investigation 2010 30:8 (533-543)

3Nephrol Dial Transplant (2009) 24: 3209–3215. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Gowrie Balasubramaniam, Edwina A. Brown, Andrew Davenport, Hugh Cairns, Barbara Cooper, Stanley L. S. Fan, Ken Farrington, Hugh Gallagher, Patrick Harnett, Sally Krausze and Simon Steddon.

4Prevalence rates and costs of metabolic syndrome and associated risk factors using employees' integrated laboratory data and health care claims. Birnbaum H.G., Mattson M.E., Kashima S., Williamson T.E. Journal of Occupational and Environmental Medicine 2011 53:1 (27-33)

4Health economics perspective of the components of the cardiometabolic syndrome Tamariz L., Palacio A., Florez H., Tamariz L., Palacio A., Yang Y., Parris D., Florez H., Tamariz L., Palacio A., Florez H., Ben-Joseph R.

4Journal of Clinical Hypertension 2010 12:7 (549-555)

5Long-term economic bene¦ts attributed to IVF-conceived children: A lifetime tax calculation. Connolly M.P., Pollard M.S., Hoorens S., Kaplan B.R., Oskowitz S.P., Silber S.J., Silber S.J. American Journal of Managed Care 2008 14:9 (598-604)

5Resource allocation of in vitro fertilization: A nationwide register-based cohort study. Klemetti R., Sevón T., Hemminki E., Gissler M., Sevón T., Hemminki E. BMC Health Services Research 2007 7 Article Number 210

6Economic Analysis of Infant vs Postpubertal Orchiopexy to Prevent Testicular Cancer. Hsieh M.H., Roth D.R., Meng M.V. Urology 2009 73:4 (776-781)

7Staged reconstruction of hypospadias with chordee: Outcome and costs. Svensson H, Reychman M, Åberg M, Troëng T, Svensson H. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery 1997 31:1 (51-55)

7Proximal hypospadias comparative evaluation of staged urethroplasty (modi¦ed Thiersch Duplay followed by Mathieu) and single stage on-lay island §ap repair. Samuel M., Capps S., Worth A., Samuel M. European Urology 2001 40:4 (463-468)

8One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Mahoney E.M., Wang K., Cohen D.J., Hirsch A.T., Alberts M.J., Eagle K., Mosse F., Jackson J.D., Steg P.G., Bhatt D.L., REACH Registry Investigators Circulation. Cardiovascular quality and outcomes 2008 1:1 (38-45)

8Cost of atherothrombotic diseases - Myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease - In Germany Brüggenjürgen B., Rupprecht H.-J., Spannagl M., Berger K., Ehlken B., Smala

Not all products are registered and approved for sale in all countries or regions. Indications of use may also vary by country and region. Product images are for reference only. Please contact your country representative for product availability and information.